Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AbbVie (NY:ABBV)

189.28 -1.47 (-0.77%)
Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
81 82 Next >
3 Dividend Stocks That Are No-Brainer Buys Right Now
These stocks check off multiple boxes for investors. 
Via The Motley Fool
Is AbbVie Stock a Buy Now?
Management pivoting a $300 billion company as quickly as it has is nothing short of remarkable. 
Via The Motley Fool
5 Forever Dividend Stocks to Build Your Portfolio
These five stocks are high quality and reliable. 
Via The Motley Fool
3 Magnificent Growth Stocks to Buy Right Now
These stocks share at least two common denominators: a biopharmaceutical focus and great long-term prospects. 
Via The Motley Fool
3 Cash Cows to Boost Your Confidence During the February Chill
The market can be a tricky place. Bet on these cash cow stocks to help restore confidence and extract steady returns. 
Via InvestorPlace
AbbVie Inc. (NYSE: ABBV) Records 52-Week High Friday Morning
Via Investor Brand Network
AbbVie Stock Clears Key Benchmark, Hitting 80-Plus RS Rating
A Relative Strength Rating upgrade for AbbVie shows improving technical performance. 
Via Investor's Business Daily
AbbVie Options Trading: A Deep Dive into Market Sentiment
Via Benzinga
AbbVie Inc. (NYSE: ABBV) Records 52-Week High Wednesday Morning
Via Investor Brand Network
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Beyond Nvidia: How To Navigate Investing In Your 40s — Insights From Reddit
A Reddit user reached out to the community seeking advice beyond the hunt for the "next NVIDIA Corp." Here's a sample of the responses. 
Via Benzinga
$100 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
Via Benzinga
2 Magnificent Dividend Growth Stocks to Load Up On Right Now
These two dividend-growth stocks are fantastic buys. 
Via The Motley Fool
AbbVie Analysts Boost Their Forecasts Following Strong Earnings
AbbVie Inc (NYSE: ABBV) reported better-than-expected fourth-quarter earnings on Friday. 
Via Benzinga
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
From FN Media Group LLC
Via GlobeNewswire
The 7 Best Momentum Stocks You Can Purchase Today
If you’re looking for hot opportunities in the market, here are just a few of the best momentum stocks to buy today. 
Via InvestorPlace
Is It Too Late to Buy These 2 Brilliant Passive Income Stocks?
These incredible businesses have long histories of successes behind them, and more to come. 
Via The Motley Fool
These 17 Words From AbbVie's CEO Explain Why the Stock Is Still a Buy
The drugmaker is handling its biggest obstacle yet relatively well. 
Via The Motley Fool
Jim Cramer Looks At Blackstone, Praises MercadoLibre: 'They're Incredibly Smart'
On CNBC’s "Mad Money Lightning Round," Jim Cramer said Freeport-McMoRan Inc. (NYSE: FCX) could go higher by a "couple of points, once the Chinese start manipulating their market higher, but that’s all... 
Via Benzinga
3 Stocks Just Hit New 52-Week Highs. Should You Still Be Buying?
Letting your winners run is a proven way to generate extraordinary portfolio returns without cutting them off by taking profits. 
Via InvestorPlace
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry. 
Via InvestorPlace
7 Russell 2000 Stocks to Buy for the Next Bull Run: February 2024
Unveil these standout Russell 2000 stocks, meticulously picked to harness the potential of the evolving market landscape in the 2024 surge. 
Via InvestorPlace
UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst
UBS bullish on Axsome's Auvelity launch and pipeline, foreseeing $1 billion sales by 2030. Buy rating, $111 price target. Positive Phase 3 data for Alzheimer's Agitation and Narcolepsy. 
Via Benzinga
7 Dividend Stocks Worth Holding for the Long Haul
These dividend stocks are worth holding for the long term both for upside and income production that can add up quickly. 
Via InvestorPlace
Why AbbVie Stock Flew Higher on Monday
Investors and pundits alike continued to be impressed by the company's latest earnings report. 
Via The Motley Fool
Drug Maker AbbVie Stock Sees RS Rating Jump To 81
AbbVie stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, with an increase from 78 to 81. 
Via Investor's Business Daily
Better Dividend Stock: Pfizer vs. AbbVie
Both offer above-average yields but which can deliver the most dividend income over the long run? 
Via The Motley Fool
Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
3 Fabulous Dividend Stocks to Buy in February
These stocks offer great dividends and more. 
Via The Motley Fool
7 Dividend Stocks That Pay Me More Than $500 Per Month
These stocks pay safe, reliable, and growing dividends. 
Via The Motley Fool
< Previous 1 2
...
22 23 24 25 26 27 28 29 30
...
81 82 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.